FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Section 4.1 of the Pharmacy Act, added in 2015, says a nonresident pharmacy may not ship, mail or deliver legend drugs or devices in Pennsylvania unless it holds a certificate of registration from the State Board of Pharmacy, renewed every two years. The pharmacy must disclose its location, principal officers and pharmacist in charge (and report changes within 30 days), keep a valid home-state license, cooperate with information requests, and, before registration, submit its most recent inspection report from its home-state regulator or from NABP's Verified Pharmacy Program. It must offer a toll-free line (at least 6 days and 40 hours a week) to a pharmacist licensed in Pennsylvania or its home state, printed on each container, and report home-state discipline within 30 days. The Act defines a nonresident pharmacy as one that ships legend drugs or devices into Pennsylvania 'pursuant to a prescription order'; no separate nonresident sterile-compounding permit or Pennsylvania-licensed PIC requirement appears in §4.1.

Section 4.1 was read in the General Assembly's text of Act 699; its Purdon's (63 P.S.) section number was not confirmed. Registration is filed online through PALS (www.pals.pa.gov). Pending 2025–2026 Pharmacy Act bills (HB 60 on prescription transfers, passed House 3/19/2025; HB 980 on Board membership, passed House 4/15/2026) do not appear to change nonresident registration.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

49 Pa. Code §27.601 requires sterile and nonsterile compounding to be done in accordance with section 503A of the FD&C Act (21 U.S.C. §353a), its federal regulations, and current USP compounding chapters. When the Board adopted the rule in 2019, IRRC and the Pennsylvania Medical Society asked whether draft sections would bar dispensing 'for office use' or require patient-specific prescriptions; the Board removed those sections and said it would instead rely on the federal requirements and USP referenced in §27.601. No Pennsylvania rule sets office-use quantities or labeling, so the federal 503A standard (compounding for an identified individual patient on a prescription, plus limited anticipatory compounding) governs. §27.602 also bars compounding drugs that are essentially copies of commercially available products except as 503A allows. The State Board of Pharmacy enforces.

Pennsylvania does not state 'office use is prohibited' in so many words; the answer rests on the rule's incorporation of 503A and the Board's 2019 preamble choosing to defer to federal law. Rule dates from 2019 (older than 2 years) but no later amendment or 2024–2026 Board guidance on office use was found on the Board's announcements page. Office stock is generally the domain of 503B outsourcing facilities under federal law.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

The Pharmacy Act excludes the operations of manufacturers and distributors (as defined in the Controlled Substance, Drug, Device and Cosmetic Act) from the practice of pharmacy and from the Board's powers (§2(11), §2(12), §6(l)), and contains no outsourcing-facility registration. Pennsylvania's Wholesale Prescription Drug Distributors License Act requires a Department of Health license only to operate a facility within Pennsylvania (§4(a)), so an out-of-state facility is not covered by that license. Department of Health rule 28 Pa. Code §25.113(c) says a manufacturer or distributor of drugs that has no establishment in Pennsylvania must either obtain a registration or keep an up-to-date list of its representatives operating in Pennsylvania on file. A 503B that ships drugs into Pennsylvania on patient-specific prescriptions falls under the nonresident pharmacy registration in Pharmacy Act §4.1.

No Pennsylvania statute, rule or Board page naming an outsourcing-facility credential was found. 28 Pa. Code §25.113 dates from 1982 (possibly stale in form, but still in the Code). Controlled substances shipped into PA raise separate DEA/Department of Health registration questions not covered here. Worth confirming with the PA Department of Health (Drugs, Devices and Cosmetics) and the State Board of Pharmacy for a specific 503B.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Pennsylvania is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

Section 6 of the Controlled Substance, Drug, Device and Cosmetic Act requires annual registration with the Secretary of Health for manufacturers, distributors and retailers of controlled substances, and states that nothing in it requires registration of any practitioner registered or licensed by the appropriate State board. The Act's definition of 'practitioner' covers physicians, osteopaths, nurses and others licensed or permitted to dispense or administer controlled substances in Pennsylvania.

Primary statute text from the General Assembly's current compilation. The practitioner carve-out applies to anyone licensed by their State board, so NPs (with prescriptive authority) and PAs are also covered by the exemption.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Section 8(a) of the ABC-MAP Act requires a prescriber to query the system (1) for each patient the first time the patient is prescribed a controlled substance by that prescriber, to establish a baseline; (2) whenever the prescriber has reason to believe the patient may be abusing or diverting drugs; and (3) each time the patient is prescribed an opioid drug product or benzodiazepine. For testosterone this means a first-prescription query, with no statutory periodic re-query unless abuse or diversion is suspected. Section 8(a.1) waives repeat queries while a patient remains admitted or in observation in a licensed health care facility and waives the first-time query for nonnarcotic Schedule V drugs for epilepsy/seizure disorders. The program is run by the Pennsylvania Department of Health; dispensers must query only for opioids/benzodiazepines in listed red-flag situations (Section 7(e)).

Section 8(a) as amended Nov. 2, 2016 (Act 124); (a.1) as amended Dec. 22, 2017 (Act 79). Section 39 states the act expires December 31, 2028 (amended 2021, Act 72) unless extended - watch for reauthorization. The '35 P.S. Sec. 872.8' cross-reference is the Purdon's placement listed by PDMP TTAC ('35 Sec. 872.7/872.8').

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

49 Pa. Code 16.94 sets labeling for drugs dispensed by physicians: drug name, quantity and generic manufacturer (or NDC), practitioner name and address, date, patient name, directions, and expiration information where required. A vendor summary reports no separate dispensing permit, registration or fee, with pharmacy-level storage and records expected and delegation to PAs allowed.

Absence of a permit requirement is from a vendor summary; the labeling rule is primary.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) The Department of State says practitioners must be licensed in Pennsylvania to provide services to individuals in Pennsylvania, in person or by telehealth; extraterritorial licenses exist only for physicians in adjoining states whose practice extends across the border. (2) The practice acts and regulations do not address telemedicine, so there is no state in-person exam requirement; licensees may use telemedicine if it complies with acceptable and prevailing standards of practice. (3) No Pennsylvania-specific telehealth limit on controlled substances, including Schedule III, was found; for opioid treatment programs the Board allows the initial physical exam by telehealth with an in-person exam within 14 days. (4) IMLC: member (issuing licenses since 7/7/2025).

Act 42 of 2024 concerns insurance coverage of telemedicine, not prescribing. Pennsylvania began issuing IMLC licenses 7/7/2025 per the IMLC map. Extraterritorial license citations (63 P.S. 422.34; 49 Pa. Code 17.4) are from CCHP.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

Under 49 Pa. Code §18.402 a physician may delegate a medical service to a health care practitioner or technician if the physician knows the delegatee has the education, training, experience and continued competency to do it safely, the delegation does not create undue risk to the particular patient, the patient has been told of the delegation and does not object, and the physician assumes responsibility and is available to the delegatee as appropriate to the difficulty of the procedure, the delegatee's skill and the risk. Services requiring knowledge and skill not ordinarily possessed by non-physicians may not be delegated. The rule does not require on-site presence and does not mention cosmetic injections.

No amendment date shown on the page (accessed 2026-09-23). No PA Board of Nursing statement specific to cosmetic injectables was located. The osteopathic board has its own rules (not reviewed).

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

Pennsylvania's general delegation rule (49 Pa. Code §18.402) applies to delegated IV services: the delegatee must be competent, the patient informed, and the physician responsible and available as appropriate to the risk. A December 2025 Post & Schell review reports that LPNs with the necessary training may administer IV therapy in med spas under supervision of a physician, NP or PA, which may be in person or by electronic communication, and that the Board's position on medical assistants was pending. No Pennsylvania board statement on individual exams or standing orders for elective IVs was located.

Check with the PA State Board of Nursing for any IV-hydration guidance.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's Pennsylvania guide (2025-12-23) says the doctrine rests on Neill v. Gimbel Brothers (Pa. 1938) and 63 P.S. §422.3: an unlicensed entity employing physicians to practise is itself practising without a licence, and compliant practices must be 100% physician-owned PCs or PLLCs, subject to statutory exceptions such as hospitals. MedPath Compliance reports HB 1460 (passed the House 2025-06-10) and HB 2115 (2026) on health-care transactions and ownership.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

49 Pa. Code §18.402 allows delegation of medical services to health care practitioners or technicians whom the physician knows to be trained and competent, where the delegation poses no undue risk to the patient, the patient is informed and does not object, and the physician is responsible and available as appropriate to the procedure's difficulty and risk. No Pennsylvania rule creating a laser-operator credential or requiring on-site supervision for cosmetic lasers was located.

The rule bars delegating services that need knowledge and skill not ordinarily possessed by non-physicians; whether a given laser procedure qualifies is a judgment call. Whether estheticians may operate lasers under PA cosmetology law was not checked.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Pennsylvania requires labs to hold both a state license and a CLIA certificate, and out-of-state labs soliciting or receiving specimens that originate in Pennsylvania need a Pennsylvania license (Fox Rothschild, 2021). The Department of Health's Bureau of Laboratories uses a separate 'Clinical Laboratory Application for Out of State Laboratories' (rev. 1/2023, $100 fee); the lab director must qualify under §5.21 of the state Clinical Laboratory Regulations, and labs doing toxicology must enroll in Pennsylvania's proficiency testing program.

Out-of-state labs: yes. Contact: PA DOH Bureau of Laboratories, Exton (610-280-3464).

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Pennsylvania's rule. Pennsylvania's lab regulator (CLIA state agency) is Pennsylvania Dept. of Health, Bureau of Laboratories (RA-DHPACLIA@pa.gov, 610-280-3464). The question matters for take-home and consumer test kits, not for panels a clinician orders.

Pennsylvania requires a state lab permit (including out-of-state labs); its rule on who may order tests was not confirmed. The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Pennsylvania is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Pennsylvania does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.